Herlev Hospital

Herlev, Denmark

Herlev Hospital

Herlev, Denmark
SEARCH FILTERS
Time filter
Source Type

Patent
Herlev Hospital and Immudex ApS | Date: 2017-04-12

The present invention describes the use of nucleic acid barcodes as specific labels for MHC multimers to determine the antigen responsiveness in biological samples. After cellular selection the barcode sequence will be revealed by sequencing. This technology allows for detection of multiple (potentially >1000) different antigen-specific cells in a single sample. The technology can be used for T-cell epitope mapping, immune-recognition discovery, diagnostics tests and measuring immune reactivity after vaccination or immune-related therapies.


The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein Tryptophan2,3-dioxygenase (TDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of TDO or peptides derived thereof or TDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to TDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above.


Patent
Immudex ApS and Herlev Hospital | Date: 2017-04-19

The present invention relates to detection molecules comprising at least one binding molecule, at least one linker and at least one label, and detection methods making use of same. The invention provides a high-throughput method for detection, isolation and/or identification of specific entities or cells.


Patent
Herlev Hospital and University of Aarhus | Date: 2012-12-21

The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (Ca^(2+)) with a concentration of at least 0.1 M is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilisation of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm.


Patent
Herlev Hospital, University of Heidelberg and Rigshospitalet | Date: 2013-01-16

The present invention relates to methods for improving the diagnosis and prognosis of patients with pancreatic carcinoma by making use of specific miRNA biomarkers associated with pancreatic carcinoma that may be identified based on a blood sample, in particular a whole blood, serum or plasma sample, from an individual.


Jrogensen A.B.,Copenhagen University | Frikke-Schmidt R.,Copenhagen University | Nordestgaard B.G.,Copenhagen University | Nordestgaard B.G.,Herlev Hospital | And 2 more authors.
New England Journal of Medicine | Year: 2014

BACKGROUND: High plasma levels of nonfasting triglycerides are associated with an increased risk of ischemic cardiovascular disease. Whether lifelong low levels of nonfasting triglycerides owing to mutations in the gene encoding apolipoprotein C3 (APOC3) are associated with a reduced risk of ischemic cardiovascular disease in the general population is unknown. METHODS: Using data from 75,725 participants in two general-population studies, we first tested whether low levels of nonfasting triglycerides were associated with reduced risks of ischemic vascular disease and ischemic heart disease. Second, we tested whether loss-of-function mutations in APOC3, which were associated with reduced levels of nonfasting triglycerides, were also associated with reduced risks of ischemic vascular disease and ischemic heart disease. During follow-up, ischemic vascular disease developed in 10,797 participants, and ischemic heart disease developed in 7557 of these 10,797 participants. RESULTS: Participants with nonfasting triglyceride levels of less than 1.00 mmol per liter (90 mg per deciliter) had a significantly lower incidence of cardiovascular disease than those with levels of 4.00 mmol per liter (350 mg per deciliter) or more (hazard ratio for ischemic vascular disease, 0.43; 95% confidence interval [CI], 0.35 to 0.54; hazard ratio for ischemic heart disease, 0.40; 95% CI, 0.31 to 0.52). Heterozygosity for loss-of-function mutations in APOC3, as compared with no APOC3 mutations, was associated with a mean reduction in nonfasting triglyceride levels of 44% (P<0.001). The cumulative incidences of ischemic vascular disease and ischemic heart disease were reduced in heterozygotes as compared with noncarriers of APOC3 mutations (P=0.009 and P=0.05, respectively), with corresponding risk reductions of 41% (hazard ratio, 0.59; 95% CI, 0.41 to 0.86; P=0.007) and 36% (hazard ratio, 0.64; 95% CI, 0.41 to 0.99; P=0.04). CONCLUSIONS: Loss-of-function mutations in APOC3 were associated with low levels of triglycerides and a reduced risk of ischemic cardiovascular disease. Copyright © 2014 Massachusetts Medical Society.


Patent
Glostrup Hospital and Herlev Hospital | Date: 2011-10-21

A method for treating a patient by covering a tissue region with a electric field capable of transiently or permanently permeabilizing cells in said tissue region, comprising the steps of: a. positioning the electrodes of an electrode device in a tissue region to be treated; and b. creating a specific polarity pattern by applying to a first subset of electrodes comprising at least two electrodes a first polarity while at the same time applying to a second subset of electrodes comprising at least two electrodes a second polarity.


The present invention relates to prognostic micro RNA (miRNA) biomarkers based on a specific miRNA expression pattern, which can prove as a valuable prognostic tool to predict the survival of patients being diagnosed with pancreas cancer.


Patent
Herlev Hospital | Date: 2012-10-17

The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising PD-L1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases.


The present invention lies within the field of personalised medicine. More particular the invention relates to biomarkers useful for predicting treatment efficacy and prognosis in cancer patients. Thus the invention provides microRNAs (miRNAs) which are useful for predicting efficacy of anti-angiogenic treatment. In particular, miR-664 for the prediction of response to bevacizumab in colorectal cancer of sigmoid colon or rectum.

Loading Herlev Hospital collaborators
Loading Herlev Hospital collaborators